The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg)

Current Medicinal Chemistry

Volumn 18, Issue 34, 2011, Pages 5217-5223

  Whiteside, T L ^a   Mandapathil, M ^a   Schuler, P ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Adenosine; Anti tumor immunity; Effector T cells (Teff); Pharmacologic inhibitors; Prostaglandin E2 (PGE2); Regulatory T cells (Treg)

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE DEAMINASE; ADENYLATE CYCLASE; CD39 ANTIGEN; CYCLIC AMP; CYTOSOL RECEPTOR; PROSTAGLANDIN E2;

ARTICLE; DOWN REGULATION; EFFECTOR CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; NUCLEOTIDE METABOLISM; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION;

ADENOSINE; ANIMALS; DINOPROSTONE; HUMANS; IMMUNE TOLERANCE; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 82255161799     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798184334     Document Type: Article

References (86)

1. Eggremont, A. M. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin. Cancer Res., 2009, 15, 6745-6747.
2. Alpizar, Y. A.; Chain, B.; Collins, M. K.; Greenwood, J.; Katz, D.; Stauss, H. J.; Mitchison, N. A. Ten years of progress in vaccination against cnacer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol. Immunother, 2011, 60, 1127-1135.
3. Tatsumi, T.; Kierstead, L. S.; Ranieri, E.; Gesualdo, L.; Schena, F. P.; Finke, J. H.; Bukowski, R. M.; Mueller-Berghaus, J.; Kirkwood, J. M.; Kwok, W. W.; Storkus, W. J. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4 (+) T cell responses against MAGE-6 in HLA-DRB10401 (+) patients with renal cell carcinoma or melanoma. J. Exp. Med., 2002, 196(5), 619-628. (Pubitemid 35024440)
4. Campoli, M.; Ferrone, S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene, 2008, 27, 5869-5885.
5. Frey, A. B.; Monu, N. Signaling defects in anti-tumor T cells. Immunol. Rev., 2008, 222, 192-205. (Pubitemid 351430368)
6. Hoskin, D. W.; Mader, J. S.; Furlong, S. J.; Conrad, D. M.; Blay, J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int. J. Oncol, 2008, 32, 527-535. (Pubitemid 351330458)
7. Blay, J.; White, T. D.; Hoskin, D. W. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res., 1997, 57, 2602-2605. (Pubitemid 27283766)
8. Sitarz, R.; Leguit, R. J.; de Leng, W. W.; Morsink, F. H.; Polkowski, W. P.; Maciejewski, R.; Offerhaus, G. J.; Milne, A. N. Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines. Cell Oncol. 2009, 31, 475-485.
9. Wang, D.; Dubois, R. N. Eicosanoids and cancer. Nat. Rev. Cancer, 2010, 10, 181-193.
10. Zhang, Y.; Liu, Q.; Zhang, M.; Yu, Y.; Liu, X.; Cao, X. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J. Immunol, 2009, 182, 3801-3808.
11. Chen, W. J.; Konkel, J. E. TGF-β and "adaptive" FOXP3+ regulatory T cells. J. Mol Cell Biol., 2010, 2, 30-36.
12. Sa, G.; Das, T.; Moon, C.; Hilston, CM.; Rayman, P. A.; Rini, B. I.; Tannenbaum, C. S.; Finke, J, H. GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res., 2009, 69, 3095-3104.
13. Gabrilovich, D.; Ishida, T.; Oyama, T.; Ran, S.; Kravtsov, V.; Nadaf, S.; Carbone, D. P Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Bllood, 1998, 92, 4150-4166. (Pubitemid 28544331)
14. Doubrovina, E. S.; Doubrovin, M. M.; Vider, E.; Sisson, R. B.; O'Reilly, R. J.; Dupont, B.; Vyas, Y. M. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol, 2003, 171, 6891-6899. (Pubitemid 37532125)
15. Kim, R.; Emi, M.; Tanabe, K.; Arihiro, K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res., 2006, 66, 5527-5536. (Pubitemid 43927099)
16. Whiteside, T. L. Immune responses to malignancies. J. Allergy Clin. Immunol, 2010, 125, S272-S283.
17. Whiteside, T. L. The role of immune cells in the tumor microenvironment. Cancer Treat. Res, 2006, 130, 103-124.
18. Poschke, I.; Mougiakakos, D.; Kiessling, R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol. Immunother, 2011, 60, 1161-1171.
19. Reichert, T. E.; Strauss, L.; Wagner, E. M.; Gooding, W.; Whiteside, T. L. Signaling abnormalities and reduced proliferation of circulating and tumorinfiltrating lymphocytes in patients with oral carcinoma. Clin. Cancer Res., 2002, 8, 3137-3145. (Pubitemid 35155023)
20. Ferrone, S.; Whiteside, T. L. Tumor microenvironment and immune escape. Surg. Oncol. Clin. North. AM., 2007, 16, 755-774. (Pubitemid 350101281)
21. Whiteside, T. L. The tumor microenvironment and its role in promoting tumor growth. Oncogene, 2008, 27, 5904-5912.
22. Uppaluri, R.; Dunn, G. P.; Lewis, J. S. Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immunol, 2008, 8, 16.
23. Imai, N.; Ikeda, H.; Tawara, I.; Shiku, H. Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells. Eur. J. Immunol, 2009, 39, 241-253.
24. Oble, D. A.; Loewe, R.; Yu, P.; Mihm, M. C. Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immunol., 2009, 9, 3.
25. Fakhry, C.; Westra, W. H.; Li, S.; Cmelak, A.; Ridge, J. A.; Pinto, H.; Forastiere, A.; Gillison, M. L. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst, 2008, 100, 261-269. (Pubitemid 351480538)
26. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; Zinzindohoue, F.; Bruneval,.; Cugnenc, PH.; Trajanoski, Z.; Fridman, W. H.; Pages, F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 2006, 313(5795), 1960-1964. (Pubitemid 44498003)
27. Cupponi, A.; Wieers, G.; van Baren, N.; Coulie, PG. Tumor-infiltrating lymphocytes apparently good for melanoma patients. But why? Cancer Immunol. Immunother, 2011, 60, 1153-1160.
28. Bergmann, C.; Strauss, L.; Wang, Y.; Szczepanski, M. J.; Lang, S.; Johnson, J. T.; Whiteside, T. L. T regulatory type 1 cells (Tr1) in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Cllin. Cancer Res., 2008, 14, 3706-3715.
29. Curiel, T. J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J. R.; Zhang, L.; Burow, M.; Zhu, Y.; Wei, S.; Kryczek, I.; Daniel, B.; Gordon, A.; Myers, L.; Lackner, A.; Disis, M. L.; Knutson, K. L.; Chen, L.; Zou, W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med, 2004, 10, 942-949. (Pubitemid 39273735)
30. Strauss, L.; Bergmann, C.; Szczepanski, M.; Gooding, W.; Johnson, J. T.; Whiteside, T. L. A unique subset of CD4+CD25highFoxp3+ T cells secreting IL-10 and TGF-β1 mediates suppression in the tumor microenvironment. Cllin. Cancer Res., 2007, 13, 4345-4354.
31. Strauss, L.; Bergmann, C.; Gooding, W.; Johnson, J. T.; Whiteside, T. L. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res., 2007, 13, 6301-6311. (Pubitemid 350075018)
32. Nishikawa, H.; Sakaguchi, S. Regulatory T cells in tumor immunity. Int. J. Cancer, 2010, 127, 759-767.
33. Mougiakakos, D.; Choudhury, A.; Lladser, A.; Kiessling, R.; Johansson, C. C. Regulatory T cells in cancer. Adv. Cancer Res., 2010, 107, 57-117.
34. Czystowska, M.; Strauss, L.; Bergmann, C.; Szajnik, M.; Rabinowich, H.; Whiteside, T. L. Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J. Mol. Med., 2010, 88, 577-588.
35. Strauss, L.; Bergmann, C.; Whiteside, T. L. Human circulating CD4+CD25highFoxp3+ Treg kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J. Immunol, 2009, 182, 1469-1480.
36. Shevach, E. M. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity, 2009, 30, 636-645.
37. Sitkovsky, M. V.; Kjaergaard, J.; Lukashev, D.; Ohta, A. Hypoxiaadenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin. Cancer Res., 2008, 14, 5947-5952.
38. Raimondi, G.; Turner, M. S.; Thomson, A. W.; Morel, PA. Naturally occurring regulatory T cells: recent insights in health and disease. Crit. Rev. Immunol., 2007, 27, 61-95. (Pubitemid 46659048)
39. Jonuleit, H.; Schmitt, E.; Stassen, M.; Tuehenberg, A.; Knop, J.; Enk, A. H. Identification and functional characterization of human CD4 (+) CD25 (+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med., 2001, 193, 1285-1294. (Pubitemid 32524778)
40. Roncarolo, M. G.; Gregori, S.; Battaglia, M.; Bacchetta, R.; Fleischhauer, K.; Levings, M. K. Interleukin-10 secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev., 2006, 212, 28-50. (Pubitemid 44116698)
41. Bergmann, C.; Strauss, L.; Zeidler, R.; Lang, S.; Whiteside, T. L. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res., 2007, 67, 8865-8873. (Pubitemid 47437463)
42. Roncarolo, M. G.; Bacchetta, R.; Bordignon, C.; Narula, S.; Levings, M. K. Type 1 T regulatory cells. Immunol. Rev., 2001, 182, 68-79. (Pubitemid 33070208)
43. Dannenberg, A. J.; Altorki, N. K.; Boyle, J. O.; Dang, C.; Howe, L. R.; Weksler, B. B.; Subbaramaialt, K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol, 2001, 2, 544-551. (Pubitemid 33586867)
44. Sitkovsky, M. V.; Lukashev, D.; Apasov, S.; Kojima, H.; Koshiba, M.; Caldwell, C.; Ohta, A.; Thiel, M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol, 2004, 22, 657-682. (Pubitemid 38680437)
45. Dzhandzhugazyan, K. N.; Kirkin, A. F.; thor Straten, P.; Zeuthen, J. Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Lett., 1998, 430, 227-230. (Pubitemid 28337918)
46. Zhang, B. CD73: A novel target for cancer immunotherapy. Cancer Res., 2010, 70, 6407-6411.
47. Zhang, X.; Meng, L.; He, B.; Chen, J.; Liu, P.; Zhao, J.; Zhang, Y.; Li, M.; An, D. The role of P2X7 receptor in ATP-mediated human leukemia cell death: calcium influx-independent. Acta. Biochim. Biophys. Sin., (Shanghai) 2009, 41, 362-369.
48. Sitkovsky, M.; Lukashev, D.; Deaglio, S.; Dwyer, K.; Robson, S. C.; Ohta, A. Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br. J. Pharma., 2008, 153, S457-S464. (Pubitemid 351341019)
49. Stagg, J.; Smyth, M. J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene, 2010, 29, 5346-5358.
50. Borsellino, G.; Kleinewietfeld, M.; Di Mitri, D.; Sternjak, A.; Diamantini, A.; Giometto, R.; Hopner, S.; Centonze, D.; Bernardi, G.; Dell'Acqua, M. L.; Rossini, P. M.; Battistini, L.; Rotzschke, O.; Falk, K. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood, 2007, 110, 1225-1232. (Pubitemid 47281420)
51. Deaglio, S.; Dwyer, K. M.; Gao, W.; Friedman, D.; Usheva, A.; Erat, A.; Chen, J. F.; Enjyoji, K.; Linden, J.; Oukka M.; Kuchroo, V. K.; Strom, T. B.; Robson, S. C. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med., 2007, 204, 1257-1265. (Pubitemid 46919862)
52. Mandapathil, M.; Hilldorfer, B.; Szczepanski, M. J.; Czystowska, M.; Szajnik, M.; Ren, J.; Lang, S.; Jackson, E. K.; Gorelik, E.; Whiteside, T. L. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem., 2010, 285, 7176-7186.
53. Schuler, P.; Harasymczuk, M.; Schilling, B.; Lang, S.; Whiteside, T. L. Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J. Immunol. Meth., 2011, 369, 59-68.
54. Mandapathil, M.; Szczepanski, M. J.; Szajnik, M.; Ren, J.; Jackson, E. K.; Johnson, J. T.; Gorelik, E.; Lang, S.; Whiteside, T. L. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J. Biol. Chem., 2010, 285, 27571-27580.
55. Clayton, A.; Al-Taei, S.; Webber, J.; Mason, M. D.; Tabi, Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J. Immunol., 2011, 187(2), 676-683.
56. Zhou, L.; Chong, M. W.; Littman, D. R. Plasticity of CD4+ T cell lineage differentiation. Immunity, 2009, 30, 646-655.
57. Zhang, H.; Conrad, D. M.; Butler, J. J.; Zhao, C.; Blay, J.; Hoskin, D. W. Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3', 5'-monophosphate and phosphatises. J. Immunol., 2004, 173, 932-944. (Pubitemid 38924266)
58. Bynoe, M. S.; Viret, C. FoxP3+CD4+ T cell-mediated immunosuppression involves extracellular nucleotide metabolism. Trends Immunol., 2008, 29, 99-102.
59. Bazhin, A. V.; Kahnert, S.; Kimpfler, S.; Schadendorf, D.; Umansky, V. Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells. Mol. Immunol., 2010, 47(4), 678-684.
60. Schenk, U.; Frascoli, M.; Proietti, M.; Geffers, R.; Traggiai, E.; Buer, J.; Ricordi, C.; Westendorf, A. M.; Grassi, F. AT. ATT inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors Sci. Signal., 2011, 4(162), ra12.
61. Bergmann, C.; Strauss, L.; Zeidler, R.; Lang, S.; Whiteside, T. L. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol. Immunother., 2007, 56, 1429-1442. (Pubitemid 47024702)
62. Algars, A.; Karikoski, M.; Yegutkin, G. G.; Stoitzner, P.; Niemela, J.; Salmi, M.; Jalkanen, S. Different role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood, 2011, 117, 4387-4393.
63. Kameoka, J.; Tanaka, T.; Nojima, Y.; Schlossman, S. F.; Morimoto, C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science, 1993, 261, 466-469. (Pubitemid 23276554)
64. Schrader, W. P.; West, C. A. Localization of adenosine deaminase and adenosine deaminase complexing protein in rabbit heart. Implications for adenosine metabolism. Circ. Res., 1990, 66, 754-762. (Pubitemid 20086913)
65. Dong, R. P.; Kameoka, J.; Hegen, M.; Tanaka, T.; Xu, Y.; Schlossman, S. F.; Morimoto, C. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J. Immunol., 1996, 156, 1349-1355. (Pubitemid 26065841)
66. Havre, P. A.; Abe, M.; Urasaki, Y.; Ohnuma, K.; Morimoto, C.; Dang, N. H. The role of CD26/dipeptidyl peptidase IV in cancer. Front. Biosci., 2008, 13, 1634-1645. (Pubitemid 351599721)
67. Wang, D.; Dubois, R. N. Prostaglandins and cancer. Gut., 2006, 55, 115-122. (Pubitemid 41820645)
68. Singh, B.; Cook, K. R.; Vincent, L.; Hall, C. S.; Berry, J. A.; Multani, A. S.; Lucci, A. Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J. Surg. Res., 2008, 147, 240-246.
69. Yaqub, S.; Tasken, K. Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. Crit. Rev. Oncog., 2008, 14, 57-77.
70. Su, Y.; Huang, X.; Raskovalova, T.; Zacharia, L.; Lokshin, A.; Jackson, E.; Gorelik, E. Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol. Immunother., 2008, 57, 1611-1623.
71. Sugimoto, Y.; Narumiya, S. Prostaglandin E receptors. J. Biol. Chem., 2007, 282, 11613-11617. (Pubitemid 47100657)
72. Su, Y.; Jackson, E. K.; Gorelik, E. Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol. Immunother., 2010, epub ahead of print, doi: 10.1007/s00262-010-0924-z.
73. Whiteside, T. L. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Exp. Opin. Biol. Ther., 2010, 10, 1019-1035.
74. Hasko, G.; Linden, J.; Cronstein, B.; Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune disease. Nat. Rev. Drug Discov., 2008, 7, 759-770.
75. Lev-Ari, S.; Lichtenberg, D.; Arber, N. Compositions for treatment of cancer and inflammation. Recent Pat. Anticancer Drug Discov., 2008, 3(1), 55-62. (Pubitemid 351223210)
76. Berinstein, N. L.; Wolf, G.; Naylor, P. H.; Baltzer, L.; Eagan, J. E.; et al. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol. Immunother., 2011, submitted.
77. Ghiringhelli, F.; Menard, C.; Puig, P. E.; Ladoire, S.; Roux, S.; Martin, F.; Solary, E.; Lecesne, A.; Zitvogel, L.; Chauffert, B. Metronomic cyclophosphamide regimen selectively depicts CD4+CD25+ regulatory T cells and restores T and NK effector functions in early stage cancer patients. Cancer Immunol. Immunother., 2007, 56, 641-648. (Pubitemid 46348738)
78. Morse, M. A.; Hobeika, A. C.; Osada, T.; Serra, D.; Niedzwiecki, D.; Lyerly, H. K.; Clay, T. M. Depletion of human regulatory T cells specifically enhances antigen specific immune responses to cancer vaccines. Blood, 2008, 112, 610-618.
79. Finke, J. H.; Rini, B.; Ireland, J.; Rayman, P.; Richmond, A.; Golshayan, A.; Wood, L.; Elson, P.; Garcia, J.; Dreicer, R.; Bukowski, R. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res., 2008, 14, 6674-6682.
80. DeVries, I. J.; Castelli, C.; Huygens, C.; Jacobs, J. F.; Stockis, J.; Schuler-Thurner, B.; Adema, G. J.; Punt, C. J.; Rivoltini, L.; Schuler, G.; Coulie, P. G.; Luca, S. S. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Tregdepleting agents. Clin. Cancer Res., 2010, 17, 1-8.
81. Feng, G.; Nadig, S. N.; Backdahl, L.; Beck, S.; Francis, R. S.; Schiopu, A.; Whatcott, A.; Wood, K. J.; Bushell, A. Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. Sci. Transl. Med., 2011, 3(83), 83ra40.
82. Iwatsubo, K.; Okumura, S.; Ishikawa, Y. Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling. Endocr. Metab. Immune. Disord. Drug Targets, 2006, 6, 239-247. (Pubitemid 44383207)
83. Pavan, B.; Biondi, C.; Dalpiaz, A. Adenylyl cyclases as innovative therapeutic goals. Drug Discov. Today, 2009, 14, 982-991.
84. Duan, B.; Davis, R.; Sadat, E. L.; Collins, J.; Sternweis, P. C.; Yuan, D.; Jiang, L. I. Distinct roles of adenylyl cyclase VII in regulating the immune responses in mice. J. Immunol., 2010, 185, 335-344.
85. Ernst, P. B.; Garrison, J. C.; Thompson, L. F. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J. Immunol., 2010 185, 1993-1998.
86. Greenhough, A.; Smartt, H. J.; Moore, A. E.; Roberts, H. R.; Williams, A. C.; Paraskeva, C.; Kaidi, A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 2009, 30, 377-386.